Sistema de Salut de Catalunya
Institut Català de la Salut
[Furian L] Kidney and Pancreas Transplantation Unit, Department of Surgery, Oncology and Gastroenterology DISCOG, University Hospital of Padova, Padova, Italy. [Heemann U] Abteilung für Nephrologie, Klinikum Rechts der Isar, Technische Universität München, Munich, Germany. [Bengtsson M] Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden. [Bestard O] Servei de Nefrologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Binet I] Clinic of Nephrology and Transplantation Medicine, Cantonal Hospital St Gallen, St. Gallen, Switzerland. [Böhmig GA] Division of Nephrology and Dialysis, Department of Medicine III, Medical University Vienna, Vienna, Austria
Vall d'Hebron Barcelona Hospital Campus
2025-03-18T12:29:13Z
2025-03-18T12:29:13Z
2025-01
HLA incompatible; Desensitization; Kidney transplantation
HLA incompatible; Desensibilització; Trasplantament renal
HLA incompatible; Desensibilización; Trasplante renal
Highly sensitized (HS) patients in need of kidney transplantation (KTx) typically spend a longer time waiting for compatible kidneys, are unlikely to receive an organ offer, and are at increased risk of antibody-mediated rejection (AMR). Desensitization using imlifidase, which is more rapid and removes total body immunoglobulin G (IgG) to a greater extent than other methods, enables transplantation to occur between HLA-incompatible (HLAi) donor–recipient pairs and allows patients to have greater access to KTx. However, when the project was launched there was limited data and clinical experience with desensitization in general and with imlifidase specifically. Hence, this Delphi methodology was used to reach a consensus from a multi-disciplinary team (MDT) of experts from 15 countries on the management of HS patients undergoing imlifidase HLAi from a deceased donor (DD) KTx. This Delphi consensus provides clinical practice guidance on the use of imlifidase in the end-to-end management of HS patients undergoing an HLAi DD KTx and supports centers in the development of guidelines for the utilization and integration of imlifidase into clinical practice.
The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. The authors declare that this study received funding from Hansa Biopharma for the development of this project. The funder had the following involvement with the study: logistic support for the project meetings and contracting services of an independent medical education agency to support the medical writing.
Article
Published version
English
Ronyons - Trasplantació; Rebuig (Biologia); Immunosupressió; Antígens HLA; Decisió de grup; Immunoglobulina G; ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Surgical Procedures, Operative::Transplantation::Organ Transplantation::Surgical Procedures, Operative::Kidney Transplantation; PHENOMENA AND PROCESSES::Immune System Phenomena::Transplantation Immunology::Host vs Graft Reaction::Graft Rejection; ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Biological Therapy::Immunomodulation::Immunotherapy::Immunosuppression::Desensitization, Immunologic; PSYCHIATRY AND PSYCHOLOGY::Behavior and Behavior Mechanisms::Psychology, Social::Group Processes::Consensus; CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Immunoglobulin Isotypes::Immunoglobulin G; CHEMICALS AND DRUGS::Biological Factors::Antigens::Antigens, Surface::Histocompatibility Antigens::HLA Antigens; TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::intervenciones quirúrgicas::trasplante::trasplante de órganos::intervenciones quirúrgicas::trasplante de riñón; FENÓMENOS Y PROCESOS::fenómenos del sistema inmunitario::inmunología del trasplante::reacción huésped contra injerto::rechazo del injerto; TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapia biológica::inmunomodulación::inmunoterapia::inmunosupresión::desensibilización inmunológica; PSIQUIATRÍA Y PSICOLOGÍA::conducta y mecanismos de la conducta::psicología social::procesos de grupo::consenso; COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::inmunoproteínas::inmunoglobulinas::anticuerpos::isotipos de inmunoglobulinas::inmunoglobulina G; COMPUESTOS QUÍMICOS Y DROGAS::factores biológicos::antígenos::antígenos de superficie::antígenos de histocompatibilidad::antígenos HLA
Frontiers Media
Transplant International;37
https://doi.org/10.3389/ti.2024.13886
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
Articles científics - HVH [3440]
